Zeo ScientifiX, Inc. (ZEOX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-21

Key Insights

ZEO has trained over 500 clinicians through its monthly Masterclass series in regenerative biologics treatments, demonstrating progress in building a professional practitioner network and expanding market reach in the regenerative medicine space.
The company is not listed on any major exchange (no securities registered under Section 12(b)), indicating it remains a micro-cap or OTC-traded entity with limited liquidity and institutional investor access.
This 8-K represents a non-material corporate event (Item 8.01) rather than a significant business development, suggesting the milestone announcement is primarily for awareness-building rather than disclosing financial impact or operational changes.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-09

Zeo ScientifiX has entered into an exclusive strategic collaboration with Regen Therapy, positioning Zeo as the core supplier of advanced biologic therapeutics for Regen's regenerative offerings.
The collaboration with Regen Therapy could provide Zeo with a significant revenue stream and growth opportunity in the regenerative medicine market.
The agreement seems to align with Zeo's focus on developing and supplying innovative biologic solutions, which could be a key driver of the company's future success.

Filed: 2026-04-07

ZEO ScientifiX, Inc. has been selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition, which could provide the company with increased visibility, funding, and potential partnership opportunities.
The company's selection for the XPRIZE Healthspan competition indicates its products or technologies may have promising potential in the healthcare/longevity space, which could be a growth area for the company.
Investors may want to closely monitor the company's progress in the XPRIZE competition and any subsequent updates or developments that could impact the company's future prospects.

Filed: 2026-03-27

The company has terminated the employment of its Chief Science Officer, Dr. John D. Kisiday, Ph.D., effective March 23, 2026. This could signal changes in the company's scientific leadership and strategic direction.
The filing does not provide any details or explanation for the termination of the Chief Science Officer, which raises questions about the reasons behind this decision and its potential impact on the company's operations and future prospects.
As Zeo ScientifiX, Inc. is a Nevada-based company with the ticker symbol ZEOX, investors should closely monitor any further developments or updates regarding the leadership changes and their potential implications for the company's performance and growth trajectory.

Filed: 2026-01-21

Zeo ScientifiX, Inc. granted restricted stock awards to its CEO, CFO, and Chief Medical Officer, aligning their incentives with shareholders.
The company plans to vest the stock awards over an 8-month and 1-year period, indicating a focus on long-term growth and retention.
As an OTC-listed company, Zeo ScientifiX does not trade on a major exchange, which may limit its visibility and access to capital markets.

Other reports for Zeo ScientifiX, Inc.

Annual Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.